JPWO2020056399A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020056399A5 JPWO2020056399A5 JP2021511641A JP2021511641A JPWO2020056399A5 JP WO2020056399 A5 JPWO2020056399 A5 JP WO2020056399A5 JP 2021511641 A JP2021511641 A JP 2021511641A JP 2021511641 A JP2021511641 A JP 2021511641A JP WO2020056399 A5 JPWO2020056399 A5 JP WO2020056399A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- μmol
- phospholipids
- per
- total amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 150000003904 phospholipids Chemical class 0.000 claims 15
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims 9
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical group [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 238000002347 injection Methods 0.000 claims 9
- 239000007924 injection Substances 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 5
- 208000006820 Arthralgia Diseases 0.000 claims 5
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 150000003431 steroids Chemical group 0.000 claims 4
- TZIZWYVVGLXXFV-FLRHRWPCSA-N Triamcinolone hexacetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@@H]2O TZIZWYVVGLXXFV-FLRHRWPCSA-N 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 229960004221 triamcinolone hexacetonide Drugs 0.000 claims 3
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 claims 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 2
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 claims 2
- XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 claims 2
- 229960004229 alclometasone dipropionate Drugs 0.000 claims 2
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 claims 2
- 229960002537 betamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 2
- 229960004648 betamethasone acetate Drugs 0.000 claims 2
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 claims 2
- 229960001102 betamethasone dipropionate Drugs 0.000 claims 2
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims 2
- 229960005354 betamethasone sodium phosphate Drugs 0.000 claims 2
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 claims 2
- 229960004311 betamethasone valerate Drugs 0.000 claims 2
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960001347 fluocinolone acetonide Drugs 0.000 claims 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims 2
- 229960003973 fluocortolone Drugs 0.000 claims 2
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 claims 2
- 229960002383 halcinonide Drugs 0.000 claims 2
- 229960001067 hydrocortisone acetate Drugs 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960001293 methylprednisolone acetate Drugs 0.000 claims 2
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 claims 2
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960002744 mometasone furoate Drugs 0.000 claims 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 2
- 229960004259 prednisolone tebutate Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 2
- 229960004320 triamcinolone diacetate Drugs 0.000 claims 2
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 208000033253 Autosomal systemic lupus erythematosus Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 1
- 208000031814 IgA Vasculitis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 208000027207 Whipple disease Diseases 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000007865 relapsing fever Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731941P | 2018-09-16 | 2018-09-16 | |
| US62/731,941 | 2018-09-16 | ||
| PCT/US2019/051247 WO2020056399A1 (en) | 2018-09-16 | 2019-09-16 | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500364A JP2022500364A (ja) | 2022-01-04 |
| JPWO2020056399A5 true JPWO2020056399A5 (https=) | 2024-07-22 |
| JP2022500364A5 JP2022500364A5 (https=) | 2024-07-22 |
| JP7634476B2 JP7634476B2 (ja) | 2025-02-21 |
Family
ID=68084954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511641A Active JP7634476B2 (ja) | 2018-09-16 | 2019-09-16 | 関節への送達に適した医薬組成物及びその関節痛の治療における使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12208104B2 (https=) |
| EP (1) | EP3849522A1 (https=) |
| JP (1) | JP7634476B2 (https=) |
| KR (1) | KR20210060559A (https=) |
| CN (1) | CN112702993A (https=) |
| AU (1) | AU2019339528B2 (https=) |
| BR (1) | BR112021004880A2 (https=) |
| CA (1) | CA3112234A1 (https=) |
| CL (1) | CL2021000627A1 (https=) |
| IL (1) | IL281513A (https=) |
| MX (1) | MX2021003030A (https=) |
| SG (1) | SG11202102400PA (https=) |
| TW (1) | TWI843751B (https=) |
| WO (1) | WO2020056399A1 (https=) |
| ZA (1) | ZA202101688B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3187955A1 (en) | 2020-08-05 | 2022-02-10 | Sheue-Fang Shih | Pharmaceutical composition of intra-articular corticosteroid for pain control |
| WO2024230404A1 (zh) * | 2023-05-05 | 2024-11-14 | 中南大学湘雅医院 | 一种治疗关节疼痛的氢氧化镁纳米粒、其制备方法及应用 |
| TW202519194A (zh) * | 2023-11-03 | 2025-05-16 | 台灣微脂體股份有限公司 | 用於疼痛控制之關節內皮質類固醇的微脂體組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050152962A1 (en) * | 2002-06-12 | 2005-07-14 | Metselaar Josbert M. | Composition for treatment of inflammatory disorders |
| EP1371362A1 (en) * | 2002-06-12 | 2003-12-17 | Universiteit Utrecht Holding B.V. | Composition for treatment of inflammatory disorders |
| DK2797601T3 (en) | 2012-02-10 | 2018-06-14 | Taiwan Liposome Co Ltd | PHARMACEUTICAL COMPOSITIONS FOR REDUCING COMPLICATIONS BY Ocular steroid |
| RU2677658C2 (ru) * | 2012-07-05 | 2019-01-18 | Тайвэн Липосом Ко, Лтд. | Способы лечения артрита |
-
2019
- 2019-09-16 AU AU2019339528A patent/AU2019339528B2/en active Active
- 2019-09-16 SG SG11202102400PA patent/SG11202102400PA/en unknown
- 2019-09-16 KR KR1020217011328A patent/KR20210060559A/ko not_active Ceased
- 2019-09-16 TW TW108133237A patent/TWI843751B/zh active
- 2019-09-16 JP JP2021511641A patent/JP7634476B2/ja active Active
- 2019-09-16 WO PCT/US2019/051247 patent/WO2020056399A1/en not_active Ceased
- 2019-09-16 US US17/272,387 patent/US12208104B2/en active Active
- 2019-09-16 BR BR112021004880-4A patent/BR112021004880A2/pt unknown
- 2019-09-16 MX MX2021003030A patent/MX2021003030A/es unknown
- 2019-09-16 CA CA3112234A patent/CA3112234A1/en active Pending
- 2019-09-16 EP EP19779658.4A patent/EP3849522A1/en active Pending
- 2019-09-16 CN CN201980059773.8A patent/CN112702993A/zh active Pending
-
2021
- 2021-03-12 ZA ZA2021/01688A patent/ZA202101688B/en unknown
- 2021-03-15 CL CL2021000627A patent/CL2021000627A1/es unknown
- 2021-03-15 IL IL281513A patent/IL281513A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davies et al. | Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose | |
| Lipworth et al. | Effect of ciclesonide and fluticasone on hypothalamicpituitary-adrenal axis function in adults with mild-to-moderate persistent asthma | |
| Kankaanranta et al. | Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review | |
| US20080076744A1 (en) | Method for treating inflammatory conditions with progesterone or progesterone analogs | |
| US20210128584A1 (en) | Use of glucocorticoid receptor antagonists for the treatment of amyotrophic lateral sclerosis | |
| US20030149009A1 (en) | Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration | |
| JP4623931B2 (ja) | 炎症性疾患の治療用組成物 | |
| CN104144679A (zh) | 用于治疗人类炎症性疾病的脂质体皮质类固醇 | |
| US20170281648A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
| Goldsmith et al. | Budesonide/formoterol: a review of its use in asthma | |
| ES2762243T3 (es) | Tratamiento de distrofia muscular | |
| Jarvis et al. | Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages≤ 500 µg/day in adults and adolescents with mild to moderate asthma | |
| JPWO2020056399A5 (https=) | ||
| ZA200301475B (en) | Pharmaceutical formulation of salmeterol and fluticasone propionate. | |
| CY1817A (en) | Inhalation medicaments for treating respiratory disorders | |
| Jones et al. | Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis | |
| McCormack et al. | Inhaled mometasone furoate: A review of its use in persistent asthma in adults and adolescents | |
| RU2021109952A (ru) | Фармацевтические композиции, подходящие для суставной доставки, и их применение при лечении суставной боли | |
| CN107007580A (zh) | 用于治疗肌肉萎缩症的化合物 | |
| CN1306429A (zh) | 糖皮质类固醇在制备治疗轻度/早期c opd(慢性阻塞性肺病)的药物中的应用 | |
| Vastagh et al. | Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC | |
| JPWO2022031898A5 (https=) | ||
| JP5220741B2 (ja) | アンドラスト／グルココルチコイドの併用 | |
| JP2000506175A (ja) | ホルモン補充療法のための順次併用型エストロゲン／プロゲステロンアンタゴニストの組み合わせ | |
| JPWO2022074123A5 (https=) |